Red blood cell ghosts as promising drug carriers to target wound infections

Kulzhan Berikkhanova, Rustam Omarbaev, Alexandr Gulyayev, Zarina Shulgau, Dilbar Ibrasheva, Gulsim Adilgozhina, Shynggys Sergazy, Zhaxybay Zhumadilov, Sholpan Askarova

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Autologous red blood cell ghosts (RBC ghosts) can carry cytokines to the sites of inflammation. The targeting moiety of the RBC ghosts is associated with the nature of purulent inflammation, where the erythrocytes are phagocyted and encapsulated drugs are released. In the present study we have investigated the healing potential of RBC ghosts loaded with cytokine IL-1β and antibiotic. Additionally, the pharmacokinetic properties of RBC ghosts loaded with IL-1β were studied. 35 Male Wistar rats (250-300. g) were used in the pharmacokinetic study and in a wound infection model where a suspension of Staphylococcus aureus was placed into a surgical cut of the skin and subcutaneous tissue in the femoral region. In order to monitor progression of the wound repair processes, wound swabs or aspiration biopsies were taken for analyses on the 1st-6th days. Wound repair dynamics assessment was based on suppression of S. aureus growth, signs of pain, time of disappearance of pus and infiltration around the wound. Visual observations, as well as microbiological and cytological analysis of wound exudates demonstrated a significant acceleration of healing processes in a group of animals treated with a local injection of IL-1β and ceftriaxone encapsulated into RBC ghosts when compared to the animals treated either with a local or IM injection of free drugs. For the pharmacokinetic study, single IV injections of either free or encapsulated IL-1β were made and the concentration of IL-1β in serum samples and tissue homogenates were determined. Encapsulation in RBC ghosts improved pharmacokinetic profiles of IL-1β by increasing the half-life, reducing its clearance, and increasing the deposition of the drug in the liver, spleen and lungs. These data suggest that RBC ghosts are effective drug carriers for targeted delivery of cytokines to the sites of inflammation, and have a potential for improving the treatment outcomes of purulent diseases.

Original languageEnglish
JournalMedical Engineering and Physics
DOIs
Publication statusAccepted/In press - Sep 23 2015

Fingerprint

Drug Carriers
Erythrocyte Membrane
Wound Infection
Blood
Erythrocytes
Interleukin-1
Cells
Pharmacokinetics
Wounds and Injuries
Cytokines
Inflammation
Animals
Repair
Injections
Staphylococcus aureus
Tissue
Pharmaceutical Preparations
Biopsy
Antibiotics
Suppuration

Keywords

  • Drug carriers
  • IL-1β
  • RBC ghosts
  • Wound infections

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biophysics

Cite this

Red blood cell ghosts as promising drug carriers to target wound infections. / Berikkhanova, Kulzhan; Omarbaev, Rustam; Gulyayev, Alexandr; Shulgau, Zarina; Ibrasheva, Dilbar; Adilgozhina, Gulsim; Sergazy, Shynggys; Zhumadilov, Zhaxybay; Askarova, Sholpan.

In: Medical Engineering and Physics, 23.09.2015.

Research output: Contribution to journalArticle

@article{9070d3ff821e439bad35e1f03381dfce,
title = "Red blood cell ghosts as promising drug carriers to target wound infections",
abstract = "Autologous red blood cell ghosts (RBC ghosts) can carry cytokines to the sites of inflammation. The targeting moiety of the RBC ghosts is associated with the nature of purulent inflammation, where the erythrocytes are phagocyted and encapsulated drugs are released. In the present study we have investigated the healing potential of RBC ghosts loaded with cytokine IL-1β and antibiotic. Additionally, the pharmacokinetic properties of RBC ghosts loaded with IL-1β were studied. 35 Male Wistar rats (250-300. g) were used in the pharmacokinetic study and in a wound infection model where a suspension of Staphylococcus aureus was placed into a surgical cut of the skin and subcutaneous tissue in the femoral region. In order to monitor progression of the wound repair processes, wound swabs or aspiration biopsies were taken for analyses on the 1st-6th days. Wound repair dynamics assessment was based on suppression of S. aureus growth, signs of pain, time of disappearance of pus and infiltration around the wound. Visual observations, as well as microbiological and cytological analysis of wound exudates demonstrated a significant acceleration of healing processes in a group of animals treated with a local injection of IL-1β and ceftriaxone encapsulated into RBC ghosts when compared to the animals treated either with a local or IM injection of free drugs. For the pharmacokinetic study, single IV injections of either free or encapsulated IL-1β were made and the concentration of IL-1β in serum samples and tissue homogenates were determined. Encapsulation in RBC ghosts improved pharmacokinetic profiles of IL-1β by increasing the half-life, reducing its clearance, and increasing the deposition of the drug in the liver, spleen and lungs. These data suggest that RBC ghosts are effective drug carriers for targeted delivery of cytokines to the sites of inflammation, and have a potential for improving the treatment outcomes of purulent diseases.",
keywords = "Drug carriers, IL-1β, RBC ghosts, Wound infections",
author = "Kulzhan Berikkhanova and Rustam Omarbaev and Alexandr Gulyayev and Zarina Shulgau and Dilbar Ibrasheva and Gulsim Adilgozhina and Shynggys Sergazy and Zhaxybay Zhumadilov and Sholpan Askarova",
year = "2015",
month = "9",
day = "23",
doi = "10.1016/j.medengphy.2016.02.014",
language = "English",
journal = "Medical Engineering and Physics",
issn = "1350-4533",
publisher = "Elsevier",

}

TY - JOUR

T1 - Red blood cell ghosts as promising drug carriers to target wound infections

AU - Berikkhanova, Kulzhan

AU - Omarbaev, Rustam

AU - Gulyayev, Alexandr

AU - Shulgau, Zarina

AU - Ibrasheva, Dilbar

AU - Adilgozhina, Gulsim

AU - Sergazy, Shynggys

AU - Zhumadilov, Zhaxybay

AU - Askarova, Sholpan

PY - 2015/9/23

Y1 - 2015/9/23

N2 - Autologous red blood cell ghosts (RBC ghosts) can carry cytokines to the sites of inflammation. The targeting moiety of the RBC ghosts is associated with the nature of purulent inflammation, where the erythrocytes are phagocyted and encapsulated drugs are released. In the present study we have investigated the healing potential of RBC ghosts loaded with cytokine IL-1β and antibiotic. Additionally, the pharmacokinetic properties of RBC ghosts loaded with IL-1β were studied. 35 Male Wistar rats (250-300. g) were used in the pharmacokinetic study and in a wound infection model where a suspension of Staphylococcus aureus was placed into a surgical cut of the skin and subcutaneous tissue in the femoral region. In order to monitor progression of the wound repair processes, wound swabs or aspiration biopsies were taken for analyses on the 1st-6th days. Wound repair dynamics assessment was based on suppression of S. aureus growth, signs of pain, time of disappearance of pus and infiltration around the wound. Visual observations, as well as microbiological and cytological analysis of wound exudates demonstrated a significant acceleration of healing processes in a group of animals treated with a local injection of IL-1β and ceftriaxone encapsulated into RBC ghosts when compared to the animals treated either with a local or IM injection of free drugs. For the pharmacokinetic study, single IV injections of either free or encapsulated IL-1β were made and the concentration of IL-1β in serum samples and tissue homogenates were determined. Encapsulation in RBC ghosts improved pharmacokinetic profiles of IL-1β by increasing the half-life, reducing its clearance, and increasing the deposition of the drug in the liver, spleen and lungs. These data suggest that RBC ghosts are effective drug carriers for targeted delivery of cytokines to the sites of inflammation, and have a potential for improving the treatment outcomes of purulent diseases.

AB - Autologous red blood cell ghosts (RBC ghosts) can carry cytokines to the sites of inflammation. The targeting moiety of the RBC ghosts is associated with the nature of purulent inflammation, where the erythrocytes are phagocyted and encapsulated drugs are released. In the present study we have investigated the healing potential of RBC ghosts loaded with cytokine IL-1β and antibiotic. Additionally, the pharmacokinetic properties of RBC ghosts loaded with IL-1β were studied. 35 Male Wistar rats (250-300. g) were used in the pharmacokinetic study and in a wound infection model where a suspension of Staphylococcus aureus was placed into a surgical cut of the skin and subcutaneous tissue in the femoral region. In order to monitor progression of the wound repair processes, wound swabs or aspiration biopsies were taken for analyses on the 1st-6th days. Wound repair dynamics assessment was based on suppression of S. aureus growth, signs of pain, time of disappearance of pus and infiltration around the wound. Visual observations, as well as microbiological and cytological analysis of wound exudates demonstrated a significant acceleration of healing processes in a group of animals treated with a local injection of IL-1β and ceftriaxone encapsulated into RBC ghosts when compared to the animals treated either with a local or IM injection of free drugs. For the pharmacokinetic study, single IV injections of either free or encapsulated IL-1β were made and the concentration of IL-1β in serum samples and tissue homogenates were determined. Encapsulation in RBC ghosts improved pharmacokinetic profiles of IL-1β by increasing the half-life, reducing its clearance, and increasing the deposition of the drug in the liver, spleen and lungs. These data suggest that RBC ghosts are effective drug carriers for targeted delivery of cytokines to the sites of inflammation, and have a potential for improving the treatment outcomes of purulent diseases.

KW - Drug carriers

KW - IL-1β

KW - RBC ghosts

KW - Wound infections

UR - http://www.scopus.com/inward/record.url?scp=84962499158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962499158&partnerID=8YFLogxK

U2 - 10.1016/j.medengphy.2016.02.014

DO - 10.1016/j.medengphy.2016.02.014

M3 - Article

AN - SCOPUS:84962499158

JO - Medical Engineering and Physics

JF - Medical Engineering and Physics

SN - 1350-4533

ER -